Optoacoustic breast imaging developer Seno Medical Instruments is highlighting results from its Imagio breast imaging system that were presented at the American Roentgen Ray Society (ARRS) meeting earlier this month.
Imagio results correlated with histopathological findings of benign and malignant breast masses in a phase III study, according to the company. In the trial, 92 patients with 94 solid or complex cystic and solid breast masses assessed as BI-RADS 3, 4, or 5 with conventional ultrasound were imaged with the Imagio system.
Five predetermined optoacoustic features (both internal and external) were evaluated for each mass, and the features were scored and correlated with benign and malignant histopathology.
Mean optoacoustic imaging scores were higher for malignant masses than benign masses with respect to all individual internal and external features, as well as for combined internal and external features. In addition, external features were more predictive of malignancy than internal ones, the company reported.
